top of page


A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

The Women’s Health Clinical Research Center at Penn Medicine is conducting a paid clinical research study to evaluate the effect on bone health for a medication that is approved for heavy menstrual bleeding associated with uterine fibroids, and for moderate to severe pain due to endometriosis.
The study medication is a tablet that is taken once daily. All study participants will receive the study drug for 48 months. Participant will complete in-person visits every six months at our office at 3737 Market Street, Philadelphia PA. At those visits you will complete a bone density scan, we will ask you questions about your health, and there may be study related blood draws and exams. There will also be scheduled phone calls between the in-person study visits. Compensation for completing every part of the study is up to $3,250.


You may be eligible for the study if you meet the following criteria:

  • 18-50 years of age

  • Diagnosed with heavy menstrual bleeding due to uterine fibroids or moderate to severe pain due to endometriosis

  • Not at-risk for pregnancy or willing to use a reliable, non-hormonal method of birth control

  • Not currently pregnant or breastfeeding

  • Additional study criteria apply

Contact information:


bottom of page